Working… Menu

Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03382574
Recruitment Status : Suspended (it was decided that due to lack of accrual on the trial, and low potential for accruing over the near future, the trial will be shut down.)
First Posted : December 26, 2017
Last Update Posted : September 16, 2021
Information provided by (Responsible Party):
National Cancer Institute (NCI)

No Study Results Posted on for this Study
Recruitment Status : Suspended
Estimated Primary Completion Date : November 20, 2021
Estimated Study Completion Date : November 20, 2021